Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,794.00
Bid: 6,778.00
Ask: 6,780.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.03%)
Open: 6,886.00
High: 6,919.00
Low: 6,736.00
Yest. Close: 6,880.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca signs major deal with Grunenthal over Zurampic

(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. The FTSE 100 firm received approval from the European Medicines

2 Jun 16 07:08

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

LONDON, June 2 (Reuters) - AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine. The British group said on Thursday up it would re

2 Jun 16 06:52

TOP NEWS: AstraZeneca Set For USD230 Million From Licensing Zurampic

2 Jun 16 06:16

Sunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco

(ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous

29 May 16 16:22

New incentives needed to develop antibiotics to fight superbugs

(Repeats May 27 story with no changes) By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial

29 May 16 11:00

New incentives needed to develop antibiotics to fight superbugs

By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the inves

27 May 16 23:52

UPDATE: AstraZeneca Gets Positive Opinion On Saxa/Dapa

27 May 16 11:44

UPDATE 1-AstraZeneca potassium drug delayed by manufacturing snag

(Adds analyst comment, further details) LONDON, May 27 (Reuters) - AstraZeneca said on Friday U.S. regulators would not approve its new drug for high potassium levels at present due to a manufacturing issue, dealing a blow to a product acquired when it bought ZS Pharma for $2.7 billion last

27 May 16 08:53

AstraZeneca gets positive breast cancer trial results; potassium drug suffers setback

(ShareCast News) - Phamaceuticals giant AstraZeneca announced positive results for its Faslodex drug for the treatment of metastatic breast cancer, but also said US regulators will not currently approve its new drug for high potassium levels because of a manufacturing issue. The company said on Frid

27 May 16 07:32

London pre-open: G7 warns of Brexit risks

(ShareCast News) - Stocks are set for a slightly lower open as traders tread cautiously ahead of a speech by Fed chair Janet Yellen towards the close of trading in London and ahead of the release of key economic indicators Stateside. The fact that investors are heading into a long weekend on both si

27 May 16 07:29

AstraZeneca potassium drug delayed by manufacturing snag

LONDON, May 27 (Reuters) - AstraZeneca said on Friday U.S. regulators would not approve its new drug for high potassium levels at present due to a manufacturing issue, dealing a blow to a product acquired when it bought ZS Pharma for $2.7 billion last year. The British drugmaker said the Fo

27 May 16 06:36

TOP NEWS: AstraZeneca Gets Good Breast Cancer Treatment Results

27 May 16 06:10

China regulator to launch drug pricing probe in June

SHANGHAI, May 27 (Reuters) - China will carry out wide-ranging pricing inspections on drug firms, hospitals and procurement bodies from June 1, the country's top watchdog said on Friday, extending a tough cost-cutting campaign to reduce the price of healthcare. The National Development and

27 May 16 02:42

UPDATE 2-FDA staff question usefulness of Sanofi diabetes drugs

(Adds details, comments from FDA reviewers) By Toni Clarke May 23 (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contrib

23 May 16 17:05

UPDATE 1-FDA staff question utility of Sanofi diabetes drugs

(Updates with details) May 23 (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned whether Sanofi SA's experimental diabetes drug lixisenatide contributed any benefit to a fixed-dose combination product the company hopes to market. The review comes ahe

23 May 16 13:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.